Beleaguered Spanish Drug Firm Grifols Stock Jumps On Monday - Here's Why In a regulatory filing, Grifols SA (NASDAQ:GRFS) said that Brookfield Capital has confirmed that it has engaged in preliminary discussions with Grifols’s key shareholders regarding a potential joint offer to delist the company’s shares from the Spanish stock exchanges and NASDAQ. Brookfield and the shareholders have signed an exclusivity agreement to explore this possibility further and requested access to certain company information to conduct due diligence. Also Read: Spanish Healthcare Firm Grifols’ Reputational Damage and Debt Woes: European Central Bank Probes Lenders. According to the information provided to the Board of Directors, Brookfield, and the Grifols family shareholders have agreed to evaluate a possible joint takeover bid to acquire Grifols. The Board of Directors held an extraordinary meeting to allow access to certain company information to carry out a due diligence process regarding the intent of the transaction, in case The board goes through, would be delisting the company. Reuters noted that the founding family members own a 30% stake in Grifols. In a regulatory filing, the Comisión Nacional del Mercado de Valores made the following decision: “Effective from 12:00 PM today, the precautionary suspension of Grifols has been lifted, applying to shares and related securities on the Stock Exchanges and Sistema de Interconexión Bursátil, Derivative contracts on these shares on MEFF Sociedad Rectora del Mercado de Productos Derivados, S.A.U., and Fixed Income Instruments issued on the CAPI OTF. Earlier, CNMV agreed to suspend the trading of Grifols shares. The suspension was lifted because sufficient information about the circumstances leading to the suspension has been made public to market operators and the CNMV.” Citing business newspaper Cinco Dias, Reuters noted that the founding family aims to gain access to the company’s books to make a final offer in the coming weeks. Reuters highlighted that the deal could be worth around 5.5 billion euros ($5.96 billion). In March, Gotham City Research released a new report on Grifols questioning the company’s “transparency, integrity and ethical conduct.” Recently, Grifols appointed Rahul Srinivasan as the new Chief Financial Officer, effective September 16. Price Action: GRFS shares are up 20.90% at $8.51 at the last check on Monday. Read Next: Grifols Gets Downgraded: Fitch, S&P Flag Cash Flow Concerns At Pharma Company. Photo via Wikimedia Commons "ACTIVE INVESTORS' SECRET WEAPON" Supercharge Your Stock Market Game with the #1 "news & everything else" trading tool: Benzinga Pro - Click here to start Your 14-Day Trial Now! Get the latest stock analysis from Benzinga? This article Beleaguered Spanish Drug Firm Grifols Stock Jumps On Monday - Here's Why originally appeared on Benzinga.com © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Beleaguered Spanish Drug Firm Grifols Stock Jumps On Monday - Here's Why
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...